Polymorphism of human cytochrome P450 enzymes and its clinical impact
Pharmacogenetics is the study of how interindividual variations in the DNA sequence of
specific genes affect drug response. This article highlights current pharmacogenetic …
specific genes affect drug response. This article highlights current pharmacogenetic …
[HTML][HTML] Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies
When To Start Consortium - The Lancet, 2009 - Elsevier
BACKGROUND: The CD4 cell count at which combination antiretroviral therapy should be
started is a central, unresolved issue in the care of HIV-1-infected patients. In the absence of …
started is a central, unresolved issue in the care of HIV-1-infected patients. In the absence of …
Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society–USA panel
Importance New data and therapeutic options warrant updated recommendations for the use
of antiretroviral drugs (ARVs) to treat or to prevent HIV infection in adults. Objective To …
of antiretroviral drugs (ARVs) to treat or to prevent HIV infection in adults. Objective To …
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label …
B Clotet, J Feinberg, J van Lunzen, MA Khuong-Josses… - The Lancet, 2014 - thelancet.com
Background Dolutegravir has been shown to be non-inferior to an integrase inhibitor and
superior to a non-nucleoside reverse transcriptase inhibitor (NNRTI). In FLAMINGO, we …
superior to a non-nucleoside reverse transcriptase inhibitor (NNRTI). In FLAMINGO, we …
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING …
F Raffi, A Rachlis, HJ Stellbrink, WD Hardy, C Torti… - The Lancet, 2013 - thelancet.com
Summary Background Dolutegravir (S/GSK1349572) is a once-daily HIV integrase inhibitor
with potent antiviral activity and a favourable safety profile. We compared dolutegravir with …
with potent antiviral activity and a favourable safety profile. We compared dolutegravir with …
[HTML][HTML] Effect of early versus deferred antiretroviral therapy for HIV on survival
MM Kitahata, SJ Gange, AG Abraham… - … England Journal of …, 2009 - Mass Medical Soc
Background The optimal time for the initiation of antiretroviral therapy for asymptomatic
patients with human immunodeficiency virus (HIV) infection is uncertain. Methods We …
patients with human immunodeficiency virus (HIV) infection is uncertain. Methods We …
[HTML][HTML] Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco
M Das, PL Chu, GM Santos, S Scheer, E Vittinghoff… - PloS one, 2010 - journals.plos.org
Background At the individual level, higher HIV viral load predicts sexual transmission risk.
We evaluated San Francisco's community viral load (CVL) as a population level marker of …
We evaluated San Francisco's community viral load (CVL) as a population level marker of …
[图书][B] Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach-2010 revision
World Health Organization - 2010 - apps.who.int
ISBN 978 92 4 459976 1(NLM classification: WC 503.2)© всемирная организация
здравоохранения, 2010 г. все права защищены. публикации всемирной организации …
здравоохранения, 2010 г. все права защищены. публикации всемирной организации …
Late presentation of HIV infection: a consensus definition
A Antinori, T Coenen, D Costagiola, N Dedes… - HIV …, 2011 - Wiley Online Library
Objectives Across Europe, almost a third of individuals infected with HIV do not enter health
care until late in the course of their infection. Surveillance to identify the extent to which late …
care until late in the course of their infection. Surveillance to identify the extent to which late …
Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on …
SW Worm, C Sabin, R Weber, P Reiss… - The Journal of …, 2010 - academic.oup.com
Background. The risk of myocardial infarction (MI) in patients with human immunodeficiency
virus (HIV) infection has been assessed in 13 anti-HIV drugs in the Data Collection on …
virus (HIV) infection has been assessed in 13 anti-HIV drugs in the Data Collection on …